When do the ADREVIEW patents expire, and when will ADREVIEW go generic?

Sponsor	Phase
University of Texas	PHASE2
Innervate Radiopharmaceuticals LLC (Formerly: Illumina Radiopharmaceuticals LLC)	PHASE2
Mayo Clinic	Phase 4

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Ge Healthcare	ADREVIEW	iobenguane sulfate i-123	SOLUTION;INTRAVENOUS	022290-001	Sep 19, 2008		RX	Yes	Yes	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

Last updated: October 2, 2026

ADreView is a U.S.-approved diagnostic radiopharmaceutical containing iobenguane I-123. Its commercial market is specialized and volume-driven, with demand linked to neuroendocrine tumor imaging, cardiac sympathetic neuronal imaging, nuclear medicine capacity, and radiopharmacy distribution. Public disclosures do not report ADreView revenue separately, so its financial trajectory cannot be quantified from company filings. The product’s value is supported by an established FDA label and clinical utility, but growth is constrained by a narrow patient population, isotope logistics, hospital imaging economics, and competition from newer diagnostic and therapeutic approaches.

What is ADreView and who markets it?

ADreView is iobenguane I-123 injection, a radioactive diagnostic agent used for planar and SPECT imaging. The product targets tissues expressing the norepinephrine transporter and is used primarily in two settings:

Localization of primary or metastatic neuroendocrine tumors.
Evaluation of cardiac sympathetic neuronal function in selected patients with heart failure.

The U.S. product was approved by the FDA in 2008. GE Healthcare has been identified as the commercial supplier and applicant associated with the product. ADreView is administered intravenously and requires specialized nuclear medicine handling, imaging equipment, radiopharmacy preparation and radiation-safety controls.[1]

ADreView product profile

Attribute	Detail
Brand	ADreView
Active ingredient	Iobenguane I-123
Dosage form	Intravenous injection
Therapeutic category	Diagnostic radiopharmaceutical
Primary imaging modality	Planar scintigraphy and SPECT
FDA approval	2008
Principal clinical uses	Neuroendocrine tumor localization; cardiac sympathetic imaging
Commercial supplier	GE Healthcare
FDA pathway	New drug application
Patent-type protection	No significant current market exclusivity is publicly evident from the approved-product profile
Revenue disclosure	No separate ADreView revenue reported in public company filings

ADreView is not a therapeutic radiopharmaceutical. It should be distinguished from iobenguane I-131 products, including AZEDRA, which is used therapeutically for certain malignant or unresectable pheochromocytoma and paraganglioma patients.[2]

What are the main market applications for ADreView?

ADreView demand comes from two distinct clinical markets.

Neuroendocrine tumor imaging

Iobenguane imaging can identify neuroendocrine tumors that take up norepinephrine analogs. The test has been used in the workup of pheochromocytoma, paraganglioma and other neuroendocrine malignancies, including assessment of metastatic disease and suitability for certain iobenguane-based therapeutic strategies.

The market is limited by the rarity of these tumors and by the increasing use of somatostatin receptor imaging. Gallium-68 DOTATATE and related positron-emission tomography agents have gained importance in neuroendocrine tumor diagnosis because of high-resolution PET imaging and strong somatostatin-receptor targeting. This has reduced the role of conventional I-123 MIBG imaging in some institutions, although MIBG remains clinically relevant when evaluating norepinephrine transporter expression or determining eligibility for MIBG-directed therapy.

Cardiac sympathetic neuronal imaging

The FDA label also covers imaging of cardiac sympathetic neuronal function in patients with New York Heart Association class II or class III heart failure and left ventricular ejection fraction of 35% or less.[1]

This indication gives ADreView access to a larger potential population than neuroendocrine tumor imaging. Commercial adoption, however, depends on reimbursement, nuclear cardiology infrastructure, clinical workflow and physician acceptance. The test has not become a routine heart-failure imaging procedure across the U.S. market. Its use is concentrated in specialist centers and institutions with established nuclear medicine programs.

How large is the ADreView market?

The addressable market is a niche segment of the broader nuclear medicine and diagnostic imaging market. Public sources do not provide a reliable standalone estimate of ADreView unit volume or sales.

The product’s market size is shaped by four variables:

The incidence of pheochromocytoma, paraganglioma and related neuroendocrine tumors.
The number of patients undergoing specialized cardiac sympathetic imaging.
The availability of I-123 production and radiopharmacy distribution.
The degree to which hospitals substitute PET-based neuroendocrine imaging.

The cardiac indication creates theoretical volume potential, but clinical use remains specialized. The neuroendocrine indication is smaller in patient count but strategically important because diagnostic MIBG uptake can influence eligibility for therapeutic iobenguane programs.

What is the financial trajectory of ADreView?

No public filing separately reports ADreView revenue, gross margin, operating profit or cash flow. GE HealthCare reports at segment and business-line levels rather than by individual radiopharmaceutical brand. As a result, ADreView’s financial trajectory must be assessed through market structure rather than reported product revenue.

Commercial trajectory

Period	Commercial interpretation
2008-2010	FDA approval established the product as a U.S. diagnostic option for MIBG imaging.
2010-2017	Revenue growth depended on adoption in neuroendocrine tumor imaging and specialized heart-failure evaluation.
2018-2021	MIBG demand faced increasing competition from PET-based neuroendocrine imaging, while therapeutic iobenguane development supported continued clinical relevance.
2022-2024	The product remained a niche radiopharmaceutical with value tied to supply reliability, specialist use and clinical pathway integration.
Forward outlook	Likely stable-to-constrained demand unless cardiac utilization expands or MIBG testing becomes more important in selecting patients for iobenguane therapy.

The product does not have the growth profile of a mass-market pharmaceutical. Its economics are more closely linked to manufacturing reliability, isotope supply, hospital ordering patterns and radiopharmacy margins.

What patents protect ADreView?

ADreView’s principal protection is regulatory and commercial rather than a clearly identifiable active patent moat. The active pharmaceutical ingredient, iobenguane, is an established chemical entity, and the product was approved more than 15 years ago.

A review of the public FDA product framework does not indicate that ADreView currently benefits from meaningful new chemical entity exclusivity. Any original patent rights associated with the compound, formulation or use would generally be expected to have expired or to be near the end of their enforceable terms, depending on the specific patent and any patent-term adjustment or extension.

Formulation and manufacturing protection

Radiopharmaceutical protection can arise from:

Isotope production and purification methods.
Radiolabeling processes.
Sterility and stability controls.
Vial configuration and dose-calibration procedures.
Distribution and radiopharmacy logistics.
Manufacturing know-how that is not publicly disclosed.

These barriers can preserve commercial position even when traditional composition-of-matter patents are no longer active. They are operational barriers rather than conventional exclusivity rights.

When does ADreView lose exclusivity?

ADreView’s principal FDA market protections have already expired or are no longer central to its commercial position. The product was approved in 2008, and the standard five-year new chemical entity exclusivity period would have ended in 2013. Any applicable orphan-drug exclusivity would depend on the indication and FDA designation history, but no current broad market exclusivity should be assumed from the approval date alone.

The more relevant question is whether an alternative supplier can reproduce the product at commercial scale while meeting radiopharmaceutical manufacturing, sterility, isotope and distribution requirements.

What is the Orange Book status of ADreView?

ADreView is an FDA-approved prescription drug product, but its practical competitive position is not determined solely by Orange Book patent listings. The product’s market is affected by radiopharmaceutical manufacturing capacity and clinical substitution.

The Orange Book should be reviewed for current patent and exclusivity entries associated with the specific approved product and applicant. Public commercial information does not support treating ADreView as a product with a significant current Orange Book patent barrier. No widely reported active Paragraph IV litigation has established a material near-term generic-entry event for ADreView.

Paragraph IV and generic-entry risk

Generic entry is possible in principle, but the commercial case is more complex than for a conventional oral drug. A competing applicant would need to address:

I-123 sourcing and isotope decay.
Radiochemical purity.
Sterility and endotoxin control.
Dose calibration at the point of administration.
Short shelf life and distribution radius.
FDA comparability requirements for a radiopharmaceutical injection.
Hospital and radiopharmacy purchasing contracts.

These factors can limit the number of viable competitors even when patent protection is weak.

Which companies challenge ADreView?

The most important competitive pressure does not come from a direct generic challenger. It comes from alternative imaging agents and therapeutic pathways.

Competitor or alternative	Company or sponsor	Market relationship to ADreView
Gallium-68 DOTATATE	Multiple commercial suppliers and radiopharmacy networks	Competes in neuroendocrine tumor imaging through somatostatin-receptor PET
Copper-64 DOTATATE	Curium and other suppliers depending on market	Provides PET-based neuroendocrine tumor imaging
AZEDRA, iobenguane I-131	Lantheus	Therapeutic product; creates potential diagnostic linkage with MIBG imaging
FDG PET	Multiple manufacturers and radiopharmacy providers	Alternative imaging approach for selected neuroendocrine and metastatic disease
Generic or compounded MIBG products	Potential regional suppliers	Could compete on price or availability if FDA-compliant supply develops

PET alternatives generally provide stronger image resolution and whole-body imaging efficiency. ADreView retains relevance where MIBG avidity is clinically important, where PET access is limited, or where physicians need to evaluate a pathway connected to iobenguane therapy.

What patent litigation affects ADreView?

No major publicly reported patent litigation appears to have materially disrupted ADreView’s U.S. market position. There is no established litigation record comparable to disputes involving high-revenue biologics or blockbuster small molecules.

The principal legal risks are more likely to involve:

Manufacturing and supply agreements.
Radiopharmacy distribution contracts.
Regulatory compliance.
Product liability.
Intellectual property related to radiolabeling or therapeutic use.
Competition involving successor products or alternative imaging agents.

The absence of major patent litigation is consistent with an older diagnostic product whose commercial value depends more on execution than on a dense patent estate.

How strong is the ADreView patent estate?

ADreView’s patent estate appears weak as a standalone exclusivity asset and stronger as an operational platform.

Patent-estate factor	Assessment
Composition-of-matter protection	Likely expired or commercially immaterial
New chemical entity exclusivity	Expired
Core formulation protection	No publicly established current barrier of major significance
Method-of-use protection	Possible historical or indication-specific protection, but not a clear current moat
Manufacturing know-how	Potentially meaningful
Isotope supply	Important practical barrier
Distribution infrastructure	Important commercial barrier
Litigation deterrence	Low based on the absence of major public disputes

A potential entrant would face less patent risk than manufacturing and supply-chain risk. That distinction matters for licensing valuation: ADreView is more attractive as a dependable radiopharmaceutical supply asset than as a patent-protected platform.

What FDA regulatory status does ADreView have?

ADreView is FDA approved for its labeled diagnostic uses. Its regulatory value comes from an established label, known safety profile, validated manufacturing controls and clinical familiarity.

Radiopharmaceutical regulation remains demanding because the product combines drug manufacturing requirements with radioactive-material controls. Suppliers must maintain:

Current good manufacturing practice compliance.
Radiochemical identity and purity.
Sterility and particulate controls.
Validated packaging and shipping.
Dose accuracy despite radioactive decay.
Controlled distribution through licensed facilities.

Supply interruptions can have an outsized commercial impact because hospitals cannot store large quantities for long periods and may not have a rapid substitute.

What generic launch scenarios exist for ADreView?

Three launch scenarios are commercially plausible.

Scenario 1: No meaningful generic entry

This is the most stable scenario. A limited patient population, specialized production and isotope logistics may not justify a broad generic launch. ADreView retains share through familiarity and supply reliability.

Scenario 2: Regional radiopharmacy competition

A regional supplier could enter selected markets where it has access to I-123 and established radiopharmacy distribution. Price pressure would be localized, with competition focused on availability and delivery time.

Scenario 3: Broader substitution by PET agents

The most significant long-term pressure may come from clinical substitution rather than a generic iobenguane product. Greater use of DOTATATE PET and other PET agents could reduce ADreView volume in neuroendocrine tumor imaging.

How does ADreView compare with AZEDRA?

ADreView and AZEDRA use related iobenguane biology but have different commercial roles.

Attribute	ADreView	AZEDRA
Isotope	I-123	I-131
Purpose	Diagnostic imaging	Therapeutic treatment
Main setting	Tumor localization and cardiac imaging	Malignant or unresectable pheochromocytoma/paraganglioma
Administration	Diagnostic injection	Therapeutic radiopharmaceutical
Revenue driver	Imaging volume and radiopharmacy use	Treatment-eligible patient volume
Competitive risk	PET substitution	Alternative systemic and targeted therapies
Clinical relationship	Can identify MIBG-avid disease	Requires MIBG-avid disease for treatment selection

The products can be commercially complementary in a MIBG-based care pathway. Increased use of therapeutic iobenguane could support diagnostic MIBG testing, but the therapeutic market remains small and highly specialized.

What is the commercial outlook for ADreView?

ADreView’s outlook is best characterized as stable but limited. Revenue is likely to remain dependent on:

Continued use in MIBG-avid neuroendocrine tumors.
Retention of specialist cardiac imaging demand.
Reliable I-123 supply.
Maintenance of radiopharmacy distribution.
Limited substitution by PET imaging.
Potential growth in MIBG-directed treatment pathways.

The product is unlikely to become a major growth driver for a diversified imaging company. Its strategic value is greater in portfolio completeness, customer retention and radiopharmaceutical infrastructure than in standalone revenue scale.

Key Takeaways

ADreView is an FDA-approved iobenguane I-123 diagnostic radiopharmaceutical.
Its principal uses are neuroendocrine tumor localization and cardiac sympathetic neuronal imaging.
GE Healthcare is the identified commercial supplier.
Separate ADreView revenue and profitability are not publicly disclosed.
Core regulatory exclusivity has expired, and no major current patent moat is evident.
Generic-entry risk is moderated by isotope supply, sterility, radiopharmacy logistics and short shelf life.
DOTATATE PET is the most important competitive pressure in neuroendocrine tumor imaging.
AZEDRA is a related therapeutic product, not a direct diagnostic substitute.
No major publicly reported patent litigation appears to have changed ADreView’s market position.
The commercial outlook is niche and operationally driven rather than patent-driven.

FAQs

Is ADreView still FDA approved?

Yes. ADreView, or iobenguane I-123 injection, remains an FDA-approved diagnostic radiopharmaceutical for labeled neuroendocrine tumor and cardiac imaging uses.[1]

Is ADreView the same as AZEDRA?

No. ADreView uses I-123 for diagnostic imaging. AZEDRA uses I-131 as a therapeutic radiopharmaceutical for selected pheochromocytoma and paraganglioma patients.[2]

Does ADreView have biosimilar competition?

No. Biosimilar regulation applies to biologic products. ADreView is a small-molecule radiopharmaceutical. Any competing product would be evaluated through a drug-approval pathway rather than a biosimilar pathway.

Can hospitals substitute DOTATATE PET for ADreView?

In some neuroendocrine tumor evaluations, clinicians may use DOTATATE PET or another PET agent instead of MIBG imaging. The choice depends on tumor biology, treatment planning, local availability and the clinical question.

Is ADreView a high-value licensing opportunity?

ADreView is more likely to have value as part of a radiopharmaceutical supply and distribution portfolio than as a patent-led licensing asset. Its commercial attractiveness depends on manufacturing reliability, isotope access, customer contracts and geographic distribution.

References

U.S. Food and Drug Administration. (2008). ADreView (iobenguane I 123 injection) prescribing information. FDA.
U.S. Food and Drug Administration. (2018). AZEDRA (iobenguane I 131 injection) prescribing information. FDA.
U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations. FDA.
National Cancer Institute. (2024). Pheochromocytoma and paraganglioma treatment. National Institutes of Health.
GE HealthCare. (2024). Pharmaceutical diagnostics and radiopharmaceutical products. GE HealthCare.

US Patents:	0
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	11
Clinical Trials:	8
Patent Applications:	635
What excipients (inactive ingredients) are in ADREVIEW?	ADREVIEW excipients list
DailyMed Link:	ADREVIEW at DailyMed

ADREVIEW Drug Patent Profile

When do Adreview patents expire, and what generic alternatives are available?

AI Deep Research

Questions you can ask:

Summary for ADREVIEW

Recent Clinical Trials for ADREVIEW

US Patents and Regulatory Information for ADREVIEW

ADreView Market Dynamics and Financial Trajectory: Iobenguane I-123 Demand, Competition, and Commercial Outlook